GNLX - NASDAQ

Genelux Corporation

GNLX·NASDAQ

$3.05

+2.7%

HealthcareBiotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$114.73M

EPS-0.8600

P/E Ratio-3.55

Earnings Date08/06/2026

gnlx

Other Current Assets

Last Annual Value

535.00K

3-Year CAGR

-29%

5-Year CAGR

10-Year CAGR

16%

Adjust for Inflation

Genelux Corporation Competitors Analysis of Other Current Assets

GNLX · NASDAQ

Company	Other Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Genelux Corporation NASDAQ:GNLX	535.00K	-19.1%	N/A	N/A
Aldeyra Therapeutics, Inc. NASDAQ:ALDX	1.34M	-34.0%	-11.8%	N/A
Codexis, Inc. NASDAQ:CDXS	6.06M	1.8%	59.9%	17.2%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	1.51M	99.1%	51.1%	26.0%
Invivyd, Inc. NASDAQ:IVVD	-23.11M	N/A	N/A	N/A
OmniAb, Inc. NASDAQ:OABI	3.93M	-1.2%	22.8%	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	4.55M	2.1%	23.9%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	3.32M	221.3%	161.8%	44.3%
Candel Therapeutics, Inc. NASDAQ:CADL	0.00	N/A	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	6.62M	1202.2%	56.9%	N/A
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	5.02M	25.9%	N/A	N/A

Genelux Corporation Fair Value Envelope

GNLX · NASDAQ

Our analysis suggests that GNLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.05, this represents a potential HIDDEN relative to our calculated worth for Genelux Corporation.

HIDDEN

Intrinsic Value

Current Price: $3.05

Related Guides

Blog Categories

Continue your GNLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.